DAKLINZA-NATDAC

Shubham Pharmaceuticals
DAKLINZA-NATDAC

Product Code : 46

 

Product Description

Daklinza: 

It contains the Drug / Molecule Daclatasvir.

DACLATASVIR has been innovated by BRISTOL MYERS SQUIBB with the brand name DAKLINZA.

 

USAGE & DESCRIPTION :

DAKLINZA has used with sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection

 

Brand Name

Daklinza

Active Ingredients

Daclatasvir

Packing

1*28

Doses Form

Tablets (IN Plastic Bottle)

Strength

30 Mg & 60 Mg

Mfg By

Bristol Myers Squibb

 

CLINICAL APPLICATIONS :

It inhibits the Hepatitis C Virus (HCV) nonstructural protein by targeting two steps of the viral replication process, enabling rapid decline of HCV RNA.

 

STORAGE :

Store DAKLINZA tablets at 25°C, with excursions permitted between 15°C and 30°C.

 

Natdac is generic version of DAKLINZA. Both contain the same Drug / molecule Daclatasvir.

 

NATDAC :

Its contains Drug / Molecule Daclatasvir.

NATDAC is generic version of DAKLINZA.

 

USAGE & DISCRIPTION :

NATDAC has used with sofosbuvir for the treatment of patients with chronic hepatitis C virus (HCV) genotype 1 or genotype 3 infection.

 

BRAND NAME

NATDAC

INTERNATIONAL BRAND NAME

DAKINZA

ACTIVE INGREDIENTS

DACLATASVIR

PACKING

1*28

DOSES FORM

TABLETS (IN PLASTIC BOTTLE)

STRENGTH

30 MG & 60 MG

MFG BY

NATCO PHARMA LIMITED. (INDIA)

 

CLINICAL APPLICATIONS :

It inhibits the Hepatitis C Virus (HCV) nonstructural protein by targeting two steps of the viral replication process, enabling rapid decline of HCV RNA.

 

STORAGE :

Store below 25°C.